The rationale for the use of ICIs in HCC relies on the fact that HCC arises in a context of chronic inflammation and an altered tumor microenvironment, with the presence of tumor-infiltrating lymphocytes expressing PD1, which is a recognized key enabling factor beyond tumor cell-intrinsic molecular aberrations [25,26,27]. Here, PDCD1 is linked to hepatocellular carcinoma.